Palopegteriparatide Benefits Sustained in Adults With Chronic Hypoparathyroidism

By News Health
6 hours Ago

(MedPage Today) — ORLANDO — Palopegteriparatide (Yorvipath) led to sustained improvements over 2 years in adults with chronic hypoparathyroidism, according to long-term phase III PaTHway trial results.
By week 104, nearly all participants…

Source link : https://www.medpagetoday.com/meetingcoverage/aace/115643

Author :

Publish date : 2025-05-18 23:20:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

GPs to help NHS find more infected blood victims

LARC Counseling Vital for Adolescent Mothers at Risk for a Short-Interval Pregnancy

Novel PDE4 Inhibitor Slows IPF Progression

Biden Diagnosed With Aggressive Cancer

'The Next World War Will Be a Biowar': What We Heard This Week

Adding CT, Symptoms Improves COPD Diagnosis